Hexarelin vs Ipamorelin: Mechanism, Potency, and Selectivity

What is the core difference between hexarelin and ipamorelin?

The core difference is receptor reach: hexarelin activates GHS-R1a and also the CD36 receptor, while ipamorelin is described as a selective GHS-R1a agonist with a cleaner hormone profile.

Both peptides belong to the growth hormone secretagogue (GHS) class. They mimic ghrelin-like signaling to prompt the pituitary to release growth hormone (GH). The practical split comes from what else each one touches. Hexarelin has a second target, CD36, a scavenger receptor found in cardiac and vascular tissue, which is why some research studies it for cardiovascular signaling rather than GH release alone (Bodart et al., 2002). Ipamorelin was characterized as one of the first GHS compounds to raise GH without meaningfully raising cortisol or prolactin (Raun et al., 1998).

How does the mechanism of each peptide work?

Hexarelin signals through two receptors, GHS-R1a and CD36; ipamorelin signals mainly through GHS-R1a alone.

GHS-R1a is the pituitary receptor that drives GH release. Both peptides bind it. Where they diverge is the second pathway. Bodart et al., 2002 identified CD36 as a receptor for hexarelin in cardiac tissue and reported that this binding is tied to cardiovascular effects that are separate from GH secretion (Bodart et al., 2002, Circulation Research, PMID 11988484). Ipamorelin does not carry this reported CD36 activity in the same way, and Raun et al., 1998 described it as selective for GH release with a limited spillover onto other pituitary hormones.

Which one is more potent, and does that matter?

Hexarelin is described in human work as producing a strong GH pulse, but potency alone does not settle the comparison because of desensitization, and no rigorous head-to-head human trial ranks the two directly.

Potency describes how strong the GH pulse is per unit given. In human studies, hexarelin produced profound GH release across several routes of administration, which is part of why it drew early research interest (Rahim et al., 1998). Ipamorelin was characterized as having GH-releasing efficacy in the range of earlier secretagogues while adding a cleaner hormone profile, raising GH while leaving cortisol and prolactin largely unchanged (Raun et al., 1998). Because these characterizations come from separate study designs rather than a direct comparison, treat any potency ranking as a qualitative literature note. The more important variable for hexarelin is durability: repeated and long-term exposure is associated with an attenuated GH response, meaning the same signal produces a smaller output over time (Rahim et al., 1998; Rahim and Shalet, 1998).

What does the research report on side-effect profile?

Ipamorelin is described as sparing cortisol and prolactin, while hexarelin's added CD36 activity and its desensitization pattern are the main points raised in its research.

For ipamorelin, Raun et al., 1998 reported that GH release occurred without the cortisol and prolactin increases seen with less selective secretagogues, which is why it is often called the more selective of the two. For hexarelin, the literature focus is different: its CD36 binding gives it cardiovascular action that is studied in its own right (Bodart et al., 2002), while separate human work reports that the GH response falls off with repeated dosing (Rahim et al., 1998; Rahim and Shalet, 1998). Neither compound has large completed human trials for cosmetic or performance use, so long-term safety in that context is not established.

Comparison grid: hexarelin vs ipamorelin

What dose ranges appear in the published research?

The published characterizations of these peptides come largely from mechanistic and early clinical work, so this section reports study context, not a protocol for any reader.

Raun et al., 1998 characterized ipamorelin's GH-releasing selectivity in laboratory models rather than as a dosing guide for humans. Bodart et al., 2002 studied hexarelin's CD36 pathway in cardiac tissue as mechanism work. Rahim et al., 1998 and Rahim and Shalet, 1998 examined hexarelin's GH response and its attenuation during longer administration in adults, which is where the desensitization picture comes from. Because there are no large completed human physique or anti-aging trials that establish safe ranges for these two compounds, this page does not list a target dose. Any personal decision about whether these peptides fit a research or clinical context, and at what amount, belongs with a qualified clinician who can weigh the full picture.